GCG and metabolic dysfunction-associated steatohepatitis: Accordingly, in a study on the murine NASH model, GLP-1 agonists improved BW, glycemic profile, hepatic enzymes, and histology as well as OS by increasing fatty acid oxidation and decreasing hepatic lipogenesis [52].